Introducing Proactive Skin Cancer Risk Assessment To Membership Care
For membership-based practices that prioritize access, preventive and personalized care, DermaSensor enables clinicians to quickly evaluate suspicious lesions during visits, providing earlier insight and enabling convenient in-office assessment.
Membership and Pricing Structure
A straightforward subscription structure makes it easy for membership-based networks to integrate skin cancer risk assessment into preventive care offerings. Contact our team to learn more about membership pricing.
-
One Monthly Membership
Simple recurring pricing aligned with membership care models. No hidden fees.
-
Visit Integration
Assess suspicious lesions during routine or preventive visits.
-
Scalable Adoption
Flexible implementation for independent or enterprise membership networks.
Why Membership Practices Choose DermaSensor
-
Preventive Care Strategy
In-office lesion evaluation enables clinicians to address skin concerns early, reinforcing proactive and preventive health management and strengthening ongoing patient relationships.
-
Immediate Results
When a new skin concern emerges, immediate skin cancer risk assessment can provide timely guidance and quick answers without patients needing to wait weeks for specialist access.
-
Personalized Care
Objective lesion information guides thoughtful conversations about skin concerns, empowering clinicians with additional insight and confidence when advising patients on monitoring or follow-up.
-
Differentiation
Adding skin lesion risk assessment expands the services available within membership programs and helps practices enhance the patient experience through innovative preventive care options.
Integrating rapid skin cancer risk assessment into member visits supports preventive care, strengthens patient reassurance, and expands the range of services offered within a personalized care model. Request a demo of DermaSensor to learn more.
Elevating the Membership Experience
Rapid In-Office Evaluation During Routine Visits
Clinicians can quickly assess suspicious lesions during membership visits, helping patients receive immediate guidance and reducing the need for additional appointments or delayed referrals.
Objective Data to Support Personalized Patient Conversations
The DermaSensor device provides a clear result of “Monitor” or “Investigate Further.” If the result is “Investigate Further,” a spectral score ranging from 1 to 10 provides additional information to support thoughtful discussions about next steps.
Non-Invasive Technology Designed for Seamless Workflow Integration
DermaSensor captures five quick spectral recordings in just 30 seconds. Clinicians can confidently assess concerning lesions without disrupting the patient experience or workflow.
FAQs About Membership-Based Care
How does DermaSensor fit within a membership-based practice model?
The device adds convenient in-office skin lesion evaluation, which supports preventive care initiatives while helping practices offer an expanded service within their membership offering.
How accurate is the device at detecting skin cancer?
Clinical studies demonstrated a 96% sensitivity for detecting all common skin cancers, including melanoma, squamous cell carcinoma, and basal cell carcinoma.
Who can operate the device in clinical practice?
Primary care physicians are qualified to use the device for rapid skin cancer risk assessment.
Does DermaSensor help reduce missed cancers?
Yes. Studies found that clinicians using the device reduced missed skin cancer referrals by 30% to 52% compared with standard evaluation alone.
How is DermaSensor different from image-based analysis?
DermaSensor uses elastic scattering spectroscopy (ESS) to analyze how light interacts with cellular structures within the lesion. This allows the device to detect biological features that cannot be seen visually or in standard images.
What skin types can DermaSensor be used on?
The device is cleared for use across all Fitzpatrick skin types, allowing clinicians to provide objective risk assessment across a broad range of skin tones.
How was the DermaSensor AI algorithm developed and validated?
The algorithm was developed and validated using over 20,000 spectral scans from more than 4,000 benign and malignant lesions.
Can DermaSensor diagnose skin cancer?
No, the device is designed to assist clinicians as an adjunctive tool for evaluating melanoma or non-melanoma skin cancers. It does not diagnose skin cancer.
Can I see a live demo of DermaSensor?
Yes, you can request an exclusive live demonstration to see how the AI-powered DermaSensor device evaluates suspicious skin lesions quickly and easily in a real clinical workflow.
80-0009.15
